A study published in the Journal of Clinical Oncology found that adding the histone deacetylase inhibitor romidepsin to the standard CHOP regimen did not improve outcomes in patients with peripheral T-cell lymphoma. The study included adult patients who received either Ro-CHOP or CHOP as frontline treatment. After a median follow-up of 6 years, there were no significant differences in progression-free survival, overall survival, or duration of response between the two groups. However, an exploratory analysis suggested a benefit for patients with TFH lymphomas in the Ro-CHOP arm. The study was supported by Celgene and the Lymphoma Academic Research Organization.
Source link
Adding Romidepsin to CHOP Yields Similar Outcomes in Patients With Previously Untreated PTCL
